Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus
Open Access
- 23 September 2004
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 12 (1) , 87-94
- https://doi.org/10.1038/sj.gt.3302387
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptorsVirology, 2004
- Gene Therapy Progress and Prospects: Noninvasive imaging of gene therapy in living subjectsGene Therapy, 2004
- Adenovirus Type 11 Uses CD46 as a Cellular ReceptorJournal of Virology, 2003
- Episomal Persistence of Recombinant Adenoviral Vector Genomes during the Cell Cycle In VivoJournal of Virology, 2003
- There Are Two Different Species B Adenovirus Receptors: sBAR, Common to Species B1 and B2 Adenoviruses, and sB2AR, Exclusively Used by Species B2 AdenovirusesJournal of Virology, 2003
- Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptidesNature Medicine, 2002
- Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K regionGene Therapy, 2001
- Three Adenovirus E3 Proteins Cooperate to Evade Apoptosis by Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptor-1 and -2Journal of Biological Chemistry, 2001
- A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivoOncogene, 2000
- Cancer Cell CyclesScience, 1996